Indoco Remedies Limited announced key auditor re-appointments for the upcoming financial year following a board meeting held on March 31, 2026. The pharmaceutical company's board approved the continuation of its existing audit partnerships to ensure regulatory compliance and internal oversight.

Board Meeting Decisions

The board meeting, which commenced at 01:00 p.m. and concluded at 01:16 p.m. on March 31, 2026, focused on auditor appointments for FY2026-27. The directors considered and approved two critical re-appointments under the provisions of Regulation 30 and Part-A of Schedule III of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Auditor Re-appointments

The company formalized the re-appointment of two key audit firms for the financial year 2026-2027:

Firm Profiles

M/s Joshi Apte and Associates operates as a firm of Cost Accountants with expertise in Cost Accountancy & Auditing, GST, and Income Tax services. The firm brings specialized knowledge in cost audit requirements for pharmaceutical companies.

M/s. Suresh Surana & Associates LLP was established in 1984 and offers comprehensive multi-disciplinary professional services. The chartered accountancy firm provides specialized services designed to meet both immediate and long-term business requirements of clients across various sectors.

Regulatory Compliance

The appointments comply with SEBI regulations, specifically Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and SEBI Master Circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024. The company has notified both the National Stock Exchange of India Limited and Bombay Stock Exchange Limited about these re-appointments as required under regulatory guidelines.

The notification was signed by Ramanathan Hariharn, Company Secretary & Head-Legal, ensuring proper documentation and compliance with listing requirements.

Indoco Remedies has informed stock exchanges about its participation in an upcoming analyst and institutional investor conference. The pharmaceutical company's senior management will attend the 11th Annual Valorem Conference, demonstrating its commitment to maintaining transparent communication with the investment community.

Conference Details

The company has provided specific details about the upcoming investor interaction:

Regulatory Compliance

Indoco Remedies has filed this intimation pursuant to Regulation 30 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015. The company has notified both the National Stock Exchange of India Limited and Bombay Stock Exchange Limited about this scheduled interaction.

Important Disclaimers

The company has emphasized several key points regarding the conference:

• Conference details are subject to change due to exigencies on the part of investors or the company
• No unpublished price sensitive information pertaining to the company will be shared during the meet with analysts and institutional investors
• The interaction follows standard regulatory protocols for investor communications

Corporate Communication

The formal communication to stock exchanges was signed by Ramanathan Hariharan, Company Secretary & Head Legal, on March 13, 2026. This advance notice provides investors and market participants with transparency about the company's upcoming investor engagement activities.

The conference participation reflects Indoco Remedies' ongoing efforts to maintain regular dialogue with the investment community while adhering to regulatory requirements for disclosure of such interactions.